Inosine 5-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients

Pediatric Transplantation

Volumn 14, Issue 7, 2010, Pages 891-895

  Ohmann, Erin L ^a   Burckart, Gilbert J ^b   Chen, Yan ^c   Pravica, Vera ^c   Brooks, Maria M ^d   Zeevi, Adriana ^a   Webber, Steven A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adverse event; haplotype; inosine 5 monophosphate dehydrogenase I; mycophenolate mofetil; pediatric heart transplantation

Indexed keywords

CYCLOSPORIN; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HAPLOTYPE; HEART GRAFT; HETEROZYGOTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEDIATRICS; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; VOMITING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GASTROINTESTINAL TRACT; HAPLOTYPES; HEART TRANSPLANTATION; HETEROZYGOTE; HUMANS; IMP DEHYDROGENASE; INFANT; LINKAGE DISEQUILIBRIUM; MALE; MYCOPHENOLIC ACID; PEDIATRICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 78349278069     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01367.x     Document Type: Article

References (21)

1. Galiwango PJ, Delgado DH, Yan R, et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant 2008: 27: 72-77.
2. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102-107.
3. Knoll GA, Macdonald I, Khan A, Van Walraven C,. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381-2386.
4. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.[see comment]. Transplantation 1999: 68: 261-266.
5. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD,. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: Does the MPA level matter? Am J Transplant 2004: 4: 1495-1500.
6. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis 2008: 51: 478-486.
7. Hesselink DA, Van Gelder T,. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005: 78: 317-321.
8. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007: 63: 1161-1169. (Pubitemid 350112768)
9. Sanchez-Fructuoso AI, Maestro ML, Calvo N, et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 2009: 41: 2313-2316.
10. Ohmann E, Burckart G, Brooks M, et al. Genetic polymorphisms influence mycophenolate mofetil related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 2010: 29: 509-516.
11. Liu N, Zhang K, Zhao H,. Haplotype-association analysis. Adv Genet 2008: 60: 335-405.
12. Excoffier L, Laval G, Schneider S,. Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evol Bioinform Online 2005: 1: 47-50.
13. Butani L, Palmer J, Baluarte HJ, Polinsky MS,. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999: 68: 83-86.
14. Dipchand AI, Benson L, Mccrindle BW, Coles J, West L,. Mycophenolate mofetil in pediatric heart transplant recipients: A single-center experience. Pediatr Transplant 2001: 5: 112-118.
15. Little J, Higgins JPT, Ioannidis JPA, et al. Strengthening the Reporting of Genetic Association studies (STREGA): An extension of the STROBE statement. Eur J Clin Invest 2009: 39: 247-266.
16. Allison AC, Eugui EM,. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993: 7: 96-112.
17. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation 1998: 66: 1115-1116.
18. Neerman MF, Boothe DM,. A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid.[erratum appears in Pharmacol Res. 2003 Oct;48(4):415]. Pharmacol Res 2003: 47: 523-526.
19. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008: 83: 711-717.
20. Girnita DM, Brooks MM, Webber SA, et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: A multi-institutional study. Transplantation 2008: 85: 1632-1639.
21. Girnita DM, Webber SA, Ferrell R, et al. Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 2006: 82: 1774-1780.